title: Prognostic impact of interferon alpha-induced cytogenetic remission in chronic myelogenous leukaemia: long-term follow-up.
abstract: To evaluate the long-term impact of the reduction of Philadelphia chromosome (Ph)-positive metaphases by treatment of chronic myelogenous leukaemia (CML) with interferon (IFN) alpha, we examined the outcome of 62 patients who had been enrolled between 1984 and 1990 into 2 IFN trials at our institution. As best cytogenetic response, 9 patients had achieved a complete remission and an additional 9 patients a partial remission. The remaining 44 patients had obtained either a minimal (n=29) or no cytogenetic response (n=15). Of the total of 62 patients, 9 were still on schedule and responsive to IFN in January 1995, including 7 patients in ongoing complete cytogenetic remission. The overall 5-year survival rate after a median follow-up from diagnosis of 51 months (range 3-102 months) was 62% and the median survival was reached at month 87. The effect of cytogenetic remission on survival was examined by "landmark" studies showing a significant survival advantage for patients with karyotype responses. In conclusion, in the patients studied, cytogenetic improvement was found to translate into improved survival expectancy. Long-term control by IFN alpha of CML, however, was restricted to a small minority of patients, predominantly to those attaining a complete suppression of the leukaemic cell clone as judged by cytogenetic criteria.
authors.affiliation: Department of Internal Medicine (Cancer Research), West German Cancer Center Essen, University of Essen Medical School, Germany.
authors.forename: O
authors.initials: O
authors.lastname: Kloke
authors.forename: N
authors.initials: N
authors.lastname: Niederle
authors.forename: B
authors.initials: B
authors.lastname: Opalka
authors.forename: I
authors.initials: I
authors.lastname: Hawig
authors.forename: S
authors.initials: S
authors.lastname: Seeber
authors.forename: R
authors.initials: R
authors.lastname: Becher
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D005821:Genetic Techniques; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008677:Metaphase; D008875:Middle Aged; D010677:Philadelphia Chromosome; D011237:Predictive Value of Tests; D011379:Prognosis; D011994:Recombinant Proteins; D012074:Remission Induction; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins